has function has role vaccinated in route immunizes against disease immunizes recipient ovarian cancer Homo sapiens subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role ovarian cancer vaccine therapeutic cancer vaccine MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine cancer vaccine A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery. Gene name: MAGE-A1 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6306 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775 2348 6306 2064 4100 Gene name: HER2-neu Gene name: FBP Hayleigh Kahn NCT: https://clinicaltrials.gov/study/NCT00373217 Jie Zheng